ResearcherChinese Academy of Medical Sciences & Peking Union Medical CollegeActive in the last 2 years
Jingyong Xu
Matched on ORCID iD 0000-0003-4942-2557; OpenAlex author ID A5039696195. Sources: OpenAlex.
Their work
- Papers
- 7
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 13
2019: 1 paper · 2020: none · 2021: 1 paper · 2022: 2 papers · 2023: none · 2024: none · 2025: 3 papers
Papers 7
- Prognostic significance of three lymph node staging systems in pancreatic cancer with ≤ 12 and > 12 retrieved lymph nodes. Co-author DOI 10.1007/s13304-025-02075-7↗
- Tumor-derived miR-203a-3p potentiates muscle wasting by inducing muscle ferroptosis in pancreatic cancer. Co-author DOI 10.1016/j.canlet.2025.217523↗
- DNMT1-Induced Downregulation of CBX7 Inhibits ERK Phosphorylation and Promotes Pancreatic Ductal Adenocarcinoma Progression. Co-author DOI 10.1096/fj.202402903r↗
- Identifying optimal candidates for tumor resection among borderline and locally advanced pancreatic cancer: A population-based predictive model. Co-author DOI 10.1016/j.pan.2022.01.004↗
- Lymph node ratio is a superior predictor in surgically treated early-onset pancreatic cancer. Co-author DOI 10.3389/fonc.2022.975846↗
- Effects of Total Pancreatectomy on Survival of Patients With Pancreatic Ductal Adenocarcinoma: A Population-Based Study. Co-author DOI 10.3389/fsurg.2021.804785↗
- Fatal Liver Infection Caused By Clostridium perfringens After Common Bile Duct Stenting Due To Pancreatic Cancer: A Case Report. Co-author DOI 10.2147/idr.s219472↗
Closest collaborators
The 13 strongest of 13 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Jinghai Song · 5 shared papers, 2021–2025 · strength 0.98
- Paper Prognostic significance of three lymph node staging systems in pancreatic cancer with ≤ 12 and > 12 retrieved lymph nod… DOI 10.1007/s13304-025-02075-7↗
- Paper DNMT1-Induced Downregulation of CBX7 Inhibits ERK Phosphorylation and Promotes Pancreatic Ductal Adenocarcinoma Progres… DOI 10.1096/fj.202402903r↗
- Paper Lymph node ratio is a superior predictor in surgically treated early-onset pancreatic cancer. DOI 10.3389/fonc.2022.975846↗
- Yangyang Zheng · 3 shared papers, 2022–2025 · strength 0.68
- Paper Prognostic significance of three lymph node staging systems in pancreatic cancer with ≤ 12 and > 12 retrieved lymph nod… DOI 10.1007/s13304-025-02075-7↗
- Paper DNMT1-Induced Downregulation of CBX7 Inhibits ERK Phosphorylation and Promotes Pancreatic Ductal Adenocarcinoma Progres… DOI 10.1096/fj.202402903r↗
- Paper Lymph node ratio is a superior predictor in surgically treated early-onset pancreatic cancer. DOI 10.3389/fonc.2022.975846↗
- Haowei Shi · 2 shared papers, 2025 · strength 0.51
- Paper Prognostic significance of three lymph node staging systems in pancreatic cancer with ≤ 12 and > 12 retrieved lymph nod… DOI 10.1007/s13304-025-02075-7↗
- Paper DNMT1-Induced Downregulation of CBX7 Inhibits ERK Phosphorylation and Promotes Pancreatic Ductal Adenocarcinoma Progres… DOI 10.1096/fj.202402903r↗
- Zhenhua Lu · 3 shared papers, 2021–2022 · strength 0.47
- Paper Lymph node ratio is a superior predictor in surgically treated early-onset pancreatic cancer. DOI 10.3389/fonc.2022.975846↗
- Paper Identifying optimal candidates for tumor resection among borderline and locally advanced pancreatic cancer: A populatio… DOI 10.1016/j.pan.2022.01.004↗
- Paper Effects of Total Pancreatectomy on Survival of Patients With Pancreatic Ductal Adenocarcinoma: A Population-Based Study. DOI 10.3389/fsurg.2021.804785↗
- Weiwei Shao · 2 shared papers, 2021–2022 · strength 0.30
- Paper Identifying optimal candidates for tumor resection among borderline and locally advanced pancreatic cancer: A populatio… DOI 10.1016/j.pan.2022.01.004↗
- Paper Effects of Total Pancreatectomy on Survival of Patients With Pancreatic Ductal Adenocarcinoma: A Population-Based Study. DOI 10.3389/fsurg.2021.804785↗
- Yumeng Hu · 1 shared paper, 2025 · strength 0.22
- Shaobo Zhang · 1 shared paper, 2025 · strength 0.22
- Zhihua Liu · 1 shared paper, 2025 · strength 0.22
- Mingyang Liu · 1 shared paper, 2025 · strength 0.22
- Fangxia Wang · 1 shared paper, 2025 · strength 0.22
- Yongxing Du · 1 shared paper, 2025 · strength 0.22
- Yanbin Wang · 1 shared paper, 2019 · strength 0.14
- Jian Chen · 1 shared paper, 2019 · strength 0.14
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.